Sign in

You're signed outSign in or to get full access.

Martha Goss

About Martha Clark Goss

Independent Director of Neuberger Berman High Yield Strategies Fund Inc. (NHS); Director since 2007 (also NRO since 2007; NML since 2013). Born 1949, long-tenured investment and risk executive, former CFO (Booz Allen) and senior leader at Prudential (Treasurer; President of investment units; Enterprise Risk Officer). Audit Committee financial expert; currently chairs Governance & Nominating Committee and serves as Audit Committee Vice Chair .

Past Roles

OrganizationRoleTenureCommittees/Impact
Booz-Allen & Hamilton, Inc.Chief Financial Officer1995–1999Senior finance leadership
Prudential Insurance CompanyTreasurer1983–1989Corporate treasury leadership
Prudential Power FundingPresident (utility and energy investing)1989–1992Led investments in electric/gas utilities & alternative energy
Prudential Asset Management CompanyPresident1992–1994Asset management leadership
Prudential InsuranceEnterprise Risk Officer1994–1995Enterprise risk oversight
Resources Global ProfessionalsConsultant2002–2006Advisory experience
Woodhill Enterprises Inc./Chase Hollow Associates LLCPresident (personal investment vehicle)2006–2020Investment management

External Roles

OrganizationRoleTenureType
American WaterDirectorSince 2003Public utility board service
Allianz Life of New YorkDirectorSince 2005Insurance board service
Museum of American FinanceDirectorSince 2013Non-profit governance
Brown UniversityTrustee EmeritaSince 1998Academic governance
Berger Group Holdings, Inc.Director2013–2018Engineering consulting (prior)
Channel ReinsuranceNon-Executive Chair & Director2006–2010Reinsurance (prior)
Ocwen Financial CorporationDirector2005–2010Mortgage servicing (prior)
Claire’s Stores, Inc.Director2005–2007Retail (prior)
Parsons Brinckerhoff Inc.Director2007–2010Engineering consulting (prior)
Bank LeumiDirector2005–2007Commercial bank (prior)
Foster Wheeler ManufacturingDirector1994–2004Industrial (prior)
Dexter Corp.Director1992–2001Manufacturing (prior)
Financial Women’s Association of New YorkDirector1987–1996; 2003–2019Non-profit leadership (prior)
AttensityAdvisory Board Member2005–2007Software (prior)

Board Governance

  • Structure and independence: Independent Chair of the Board (Tom D. Seip); Independent Directors meet outside management and are advised by independent counsel; Governance & Nominating oversees director compensation recommendations (no standing compensation committee) .
  • Committees and roles (FY2024 activity):
    • Audit Committee: Vice Chair (Goss); committee met 7 times; Goss designated audit committee financial expert .
    • Governance & Nominating Committee: Chair (Goss); NHS Governance & Nominating met 5 times .
    • Executive Committee: Member; did not meet in FY2024 .
    • Investment Performance Committee: All directors are members; met 4 times .
  • Attendance: Boards met 4 times; each Director attended at least 75% of Board and committee meetings; no policy requiring attendance at annual meeting, and none of the Board attended the 2024 Annual Meeting .

Fixed Compensation

  • The Boards do not have a standing compensation committee; Governance & Nominating Committees consider and recommend Independent Director compensation to the Boards. Specific director cash/equity retainer amounts are not disclosed in this proxy .

Performance Compensation

Performance-linked elementDisclosureNotes
Director performance metrics tied to pay (e.g., TSR, ESG)Not disclosedNo performance metrics for director pay identified in proxy

Other Directorships & Interlocks

  • Current public-company board: American Water (since 2003) .
  • Additional boards span insurance (Allianz Life of New York), infrastructure/engineering, finance, and academia; no disclosed related-party transactions with NBIA, underwriters, or affiliates for Independent Directors (including immediate family) as of July 31, 2025 .

Expertise & Qualifications

  • Financial leadership: Former CFO (Booz Allen), Treasurer and President roles at Prudential; extensive investment, risk, and corporate finance experience .
  • Designated Audit Committee financial expert (technical accounting/valuation oversight experience) .
  • Broad governance experience across profit and non-profit boards, including five NYSE-listed companies .

Equity Ownership

As of July 31, 2025NRONHSNMLAggregate across NB registered investment companies
Dollar range of equity securities ownedNone None None Over $100,000
  • Independence of holdings: No Independent Director (or immediate family) owned securities of NBIA, principal underwriters, or persons under common control with NBIA, as of July 31, 2025 .

Governance Assessment

  • Strengths:

    • Deep finance, risk, and investment background; designated financial expert enhances audit oversight quality .
    • Leadership roles (Audit Vice Chair; Governance & Nominating Chair) indicate high engagement in board effectiveness, nominations, and compensation oversight processes .
    • Committee activity levels (Audit 7x; Governance & Nominating 5x; Investment Performance 4x) combined with ≥75% attendance suggest consistent participation .
    • Independence affirmed; independent Board leadership and regular executive sessions without management .
  • Potential investor-confidence considerations:

    • No direct ownership in NHS (and sibling funds NRO, NML) as of July 31, 2025—may signal weaker fund-specific alignment versus aggregate complex exposure; disclosed aggregate >$100,000 across registered investment companies overseen .
    • No formal policy on director attendance at annual meetings and none attended in 2024—can be perceived as lower public-facing engagement, though not uncommon in funds .
  • Conflicts/related-party exposure:

    • Independent Directors (including Goss) and immediate family did not own NBIA or underwriter securities; no related-party transactions disclosed—low conflict risk based on proxy .
  • Tenure/refresh dynamics:

    • Director since 2007 at NHS; fund retirement policy generally requires retirement by end of year in which a director turns 77, providing a defined horizon for succession planning .